0.016  0 (0%)		06-17 16:00
Open: 0.0211 High: 0.0282 Volume: 120,553,903		Pre. Close: 0.016 Low: 0.0151 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	0.02	1-year :	0.03
Resists	First :	0.02	Second :	0.02
Pivot price	0
Supports	First :	0.01	Second :	0.01
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0
52-week	High :	0.02	Low :	0.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LMDX ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Fri, 05 Jan 2024
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th - Yahoo Finance

Tue, 02 Jan 2024
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology - Nasdaq

Fri, 27 Oct 2023
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal - Yahoo Finance

Mon, 23 Oct 2023
LumiraDx (NASDAQ: LMDX) stock up 134% on apparently silly rumour - Dhaka Tribune

Mon, 17 Apr 2023
LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors - simplywall.st

Mon, 26 Sep 2022
Further weakness as LumiraDx (NASDAQ:LMDX) drops 15% this week, taking one-year losses to 88% - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.